
    
      This is a controlled randomized parallel assignment, masked (Participant, Care Provider,
      Investigator, Outcomes Assessor) study. Healthy infants will be assigned an Investigational
      (Formula A) experimental new milk based infant formula, or an active comparator Control
      (Formula B) Enfamil (trademark brand name) marketed milk based infant formula. The period for
      the study is 365 days (52 weeks) using repeated-measures mixed model (RMMM). Anthropometry,
      formula intake, tolerance, and stool characteristics will be assessed. Medically confirmed
      adverse events will be recorded throughout the study.
    
  